ThromboGenics, BioInvent give clinical update

Tuesday 5 June 2012

Thrombogenics NV and BioInvent International AB have decided to stop development of an early-stage anticoagulant after safety issues were identified. They have also regained a cancer asset from Roche, which has left the programme.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium